Amplia Therapeutics (ASX: ATX) — Company Overview, News & Financial Data
Amplia Therapeutics is an Australian clinical-stage biopharmaceutical company focused on developing small molecule drug candidates for the treatment of cancer and fibrotic diseases.
Amplia Therapeutics
Amplia Therapeutics is an Australian clinical-stage biopharmaceutical company focused on developing small molecule drug candidates for the treatment of cancer and fibrotic diseases. The company's primary focus is the development of proprietary Focal Adhesion Kinase (FAK) inhibitors, designed to target the microenvironment of solid tumors and fibrotic tissue. Amplia's lead drug candidate, narmafotinib (AMP945), is a highly selective FAK inhibitor being evaluated in clinical trials for advanced pancreatic cancer and non-small cell lung cancer in combination with standard care therapies and other targeted inhibitors. The company also advances pipeline assets targeting fibrosis, such as idiopathic pulmonary fibrosis, and additional oncology indications.
Snapshot
Operations
Products and/or services of Amplia Therapeutics
- Oncology Clinical Trials for Pancreatic Cancer: Clinical development of selective small molecule focal adhesion kinase inhibitors administered in combination with standard gemcitabine and nab-paclitaxel chemotherapy regimens for advanced pancreatic ductal adenocarcinoma across clinical trial centers in Australia and South Korea.
- Non-Small Cell Lung Cancer Combination Program: Phase 1b and 2b clinical evaluation testing oral focal adhesion kinase inhibitors combined with targeted KRAS G12C inhibitors to suppress adaptive resistance mechanisms in patients diagnosed with second-line advanced non-small cell lung cancer.
- Idiopathic Pulmonary Fibrosis Therapeutic Program: Translational research and clinical-stage development of small molecule kinase inhibitors designed to block focal adhesion kinase pathways, aiming to prevent extracellular matrix deposition and fibrotic scarring in progressive lung diseases.
- Dual FAK and VEGFR2 Targeted Inhibitor Assets: Preclinical drug development of dual-action small molecule candidates engineered to simultaneously inhibit focal adhesion kinase and vascular endothelial growth factor receptor 2, targeting tumor vascularization and fibrotic tumor microenvironments.
- Cancer Microenvironment Translational Research: Research operations focused on elucidating mechanisms of adaptive drug resistance, stromal remodelling, and focal adhesion kinase activation to support preclinical discovery and combination therapy design for solid tumors.
Amplia Therapeutics executive team
- Christopher J. BurnsCEO, MD & Director
- Hamish GeorgeChief Financial Officer
- Rhiannon JonesChief Operating Officer
- Jason LickliterChief Medical Officer
- Andrew John CookeCompany Secretary
Latest news about Amplia Therapeutics
Amplia Therapeutics partners with Eli Lilly on 2026 trial
AustraliaAmplia initiates Phase 2b pancreatic cancer trial
AustraliaAmplia and ANZGOG launch new ovarian cancer trial
AustraliaAmplia halts trial recruitment amidst chemotherapy toxicities
AustraliaAmplia reports breakthrough results in pancreatic cancer trial
Australia
Recent announcements
What Amplia Therapeutics (ATX) has told the market, newest first.
- Amplia Presents at CG Drug and Device Conference 2026
Key financials
Reported results for Amplia Therapeutics, in AUD.
- Market cap
- 43.6M
- Revenue (TTM)
- 4.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -160.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -13.2M | -7.7M | |
| 3.8M | -6.5M | -6.6M | |
| 4.5M | -4.4M | -4.5M | |
| 1.2M | -7.5M | -6.2M |